This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (58)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Radiation Therapy  • Surgical Oncology  • Oncology  • Head & Neck Cancer  • Neoplasms of Head & Neck  • Alert me on articles by topic

Predictors of Morbidity and Mortality

Jim Fordice, MD; Corey Kershaw, MS; Adel El-Naggar, MD; Helmuth Goepfert, MD

Arch Otolaryngol Head Neck Surg. 1999;125:149-152.

Objectives  To review 160 patients treated at a single institution for adenoid cystic carcinoma during the 20 years between 1977 and 1996, applying a consistent treatment of surgery and postoperative radiation therapy to 140 patients. To analyze factors governing treatment failure, treatment-related morbidity, and mortality.

Design  Retrospective review.

Setting  Tertiary referral center.

Patients  Seventy-seven males and 83 females aged 13 to 89 years (average age, 49.5 years).

Results and Conclusions  Combined treatment yielded an 85% locoregional freedom from relapse and disease-specific survival at 5, 10, and 15 years was 89%, 67.4%, and 39.6%, respectively. Thirty-five patients (21.9%) had distant metastases as the only site of failure. Patients treated for paranasal sinus tumor experienced the most treatment-related morbidity vs other sites. Perineural invasion of major nerves, positive margins at surgery, and solid histological features were associated with increased treatment failures. Four or more symptoms present at diagnosis, positive lymph nodes, solid histology, and perineural invasion of major nerves were associated with increased mortality from disease.

From the Departments of Head and Neck Surgery (Drs Fordice and Goepfert) and Surgical Pathology (Dr El-Naggar), University of Texas M.D. Anderson Cancer Center and Univesity of Texas Health Science Center (Ms Kershaw), Houston.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Deletion of 1p32-p36 Is the Most Frequent Genetic Change and Poor Prognostic Marker in Adenoid Cystic Carcinoma of the Salivary Glands
Rao et al.
Clin. Cancer Res. 2008;14:5181-5187.
ABSTRACT | FULL TEXT  

High expression of Polycomb group protein EZH2 predicts poor survival in salivary gland adenoid cystic carcinoma
Vekony et al.
J. Clin. Pathol. 2008;61:744-749.
ABSTRACT | FULL TEXT  

Concomitant inhibition of epidermal growth factor and vascular endothelial growth factor receptor tyrosine kinases reduces growth and metastasis of human salivary adenoid cystic carcinoma in an orthotopic nude mouse model.
Younes et al.
Molecular Cancer Therapeutics 2006;5:2696-2705.
ABSTRACT | FULL TEXT  

Tracheobronchial Adenoid Cystic Carcinoma: A Clinicopathologic Study of 14 cases
Albers et al.
Chest 2004;125:1160-1165.
ABSTRACT | FULL TEXT  

Clinicopathologic Predictors and Impact of Distant Metastasis From Adenoid Cystic Carcinoma of the Head and Neck
Sung et al.
Arch Otolaryngol Head Neck Surg 2003;129:1193-1197.
ABSTRACT | FULL TEXT  

Urokinase-Type Plasminogen Activator Receptor Expression in Adenoid Cystic Carcinoma of the Skull Base
Doerr et al.
Arch Otolaryngol Head Neck Surg 2003;129:215-218.
ABSTRACT | FULL TEXT  

Percutaneous CT-Guided Radiofrequency Ablation of an Adenoid Cystic Carcinoma of the Head and Neck
Bui and Dupuy
Am. J. Roentgenol. 2002;179:1333-1335.
FULL TEXT  

Large Scale Molecular Analysis Identifies Genes with Altered Expression in Salivary Adenoid Cystic Carcinoma
Frierson et al.
Am. J. Pathol. 2002;161:1315-1323.
ABSTRACT | FULL TEXT